RxDoctor Payments Data

Lori Gibson

Adult Health · Noblesville, INNPI 1235444209

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 27.5% of the total.

$3,437in general payments, 2019–2025

Across 207 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$947
  • Lilly USA, LLC$387
  • Bayer$201
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$173
  • GSK$168
  • AstraZeneca$119
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,437 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$31,829
Medicare patients
87
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide38$52,724
JanuviaSitagliptin Phosphate25$38,572
JardianceEmpagliflozin20$31,601
EliquisApixaban24$29,575
MounjaroTirzepatide16$25,319
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$17,936
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$10,023
Breo ElliptaFluticasone/Vilanterol19$7,853
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp15$5,808
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,096
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,764
Albuterol Sulfate HfaAlbuterol Sulfate118$2,703
Atorvastatin Calcium322$1,936
Duloxetine Hcl68$1,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$387$78,04254 claims
MerckJanuvia$51$38,57225 claims
Boehringer IngelheimJardiance$108$31,60120 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$168$30,88553 claims
PfizerEliquis$67$29,57524 claims
AbbVieSynthroid$947$1,40723 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,195128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.

Other adult health in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →